Compare · ECOR vs LIVN
ECOR vs LIVN
Side-by-side comparison of electroCore Inc. (ECOR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.05B, about 50.1x ECOR ($81.0M).
- Over the past year, ECOR is up 93.4% and LIVN is up 70.0% - ECOR leads by 23.4 points.
- ECOR has been more active in the news (6 items in the past 4 weeks vs 4 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- LivaNova PLC
- Price
- $9.67+4.65%
- $73.81+1.09%
- Market cap
- $81.0M
- $4.05B
- 1M return
- +54.60%
- +25.32%
- 1Y return
- +93.40%
- +70.04%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 6
- 4
- Recent ratings
- 2
- 20
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest ECOR
- CFO and Interim President Lev Joshua S. sold $60,003 worth of shares (6,667 units at $9.00), decreasing direct ownership by 7% to 84,889 units (SEC Form 4)
- SEC Form 144 filed by electroCore Inc.
- Director Errico Thomas J. bought $59,852 worth of shares (9,992 units at $5.99), increasing direct ownership by 3% to 360,071 units (SEC Form 4)
- CFO and Interim President Lev Joshua S. sold $19,500 worth of shares (3,000 units at $6.50), decreasing direct ownership by 3% to 91,556 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by electroCore Inc.
- electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
- electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
- SEC Form 10-Q filed by electroCore Inc.
- electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- electroCore Announces First Quarter 2026 Financial Results
Latest LIVN
- SEC Form SD filed by LivaNova PLC
- Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)
- LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
- SEC Form DEFA14A filed by LivaNova PLC